Last reviewed · How we verify
HSK39775 Monotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HSK39775 Monotherapy (HSK39775 Monotherapy) — Xizang Haisco Pharmaceutical Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HSK39775 Monotherapy TARGET | HSK39775 Monotherapy | Xizang Haisco Pharmaceutical Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HSK39775 Monotherapy CI watch — RSS
- HSK39775 Monotherapy CI watch — Atom
- HSK39775 Monotherapy CI watch — JSON
- HSK39775 Monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). HSK39775 Monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/hsk39775-monotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing